Does Dupixent Help Chronic Sinusitis?
Yes, Dupixent (dupilumab) is FDA-approved for chronic rhinosinusitis with nasal polyps (CRSwNP), a common form of chronic sinusitis involving inflamed sinuses and nasal polyps. It reduces inflammation by blocking IL-4 and IL-13 signaling, leading to fewer polyps, less congestion, and improved sense of smell. In clinical trials like LIBERTY NP SINUS-24 and SINUS-52, patients on Dupixent plus standard therapy saw polyp scores drop by 1-2 points more than placebo on a 0-8 scale, with symptom improvements lasting up to a year.[1][2]
How Does Dupixent Compare to Standard Treatments?
Standard treatments like nasal corticosteroids or surgery provide short-term relief but often fail long-term in CRSwNP. Dupixent outperforms them in trials: 57% of patients achieved a clinically meaningful polyp reduction versus 14% on placebo, and it cut the need for surgery by about 60% over 52 weeks. It's self-administered subcutaneously every two weeks after loading doses, unlike daily nasal sprays.[1][3]
Who Qualifies for Dupixent in Sinusitis?
Approval targets adults with CRSwNP inadequately controlled by intranasal corticosteroids. It's not approved for chronic sinusitis without nasal polyps (CRS-sNP). Real-world data shows benefits in severe cases, but insurers often require proof of prior treatment failure.[2][4]
What Side Effects Do Patients Report?
Common issues include injection-site reactions (10-20%), conjunctivitis (5-10%), and joint pain (1-5%). Serious risks like hypersensitivity occur rarely (<1%). Eye problems are more frequent in sinusitis patients than in asthma or eczema users, often resolving with drops.[1][3]
How Much Does Dupixent Cost for Sinusitis?
List price is about $3,800 per monthly dose, or $37,000-$45,000 annually without insurance. Copays vary; patient assistance programs from Sanofi/Regeneron can reduce costs to $0 for eligible uninsured or underinsured patients. No generic or biosimilar exists yet.[4]
When Could Cheaper Alternatives Arrive?
Dupixent's key U.S. patents expire in 2031-2035, depending on formulation and indications. Paragraph IV challenges from competitors like Amgen and Samsung Bioepis are pending FDA review for biosimilars, potentially entering post-2031 if approved. Check DrugPatentWatch.com for latest patent statuses and litigation updates.[5]
[1] FDA Label: Dupixent (dupilumab) prescribing information, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761055s053lbl.pdf
[2] Han JK et al. N Engl J Med. 2021;384(13):1255-1265. (LIBERTY NP SINUS-24 trial)
[3] Bachert C et al. Lancet. 2021;397(10287):1961-1972. (SINUS-52 trial)
[4] Dupixent HCP website: Dosing and access info, accessed 2024. https://www.dupixent.com
[5] DrugPatentWatch.com: Dupilumab patents. https://www.drugpatentwatch.com/p/tradename/DUPIXENT